The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine

被引:194
作者
Eyden, B. [1 ]
机构
[1] Christie Hosp NHS Trust, Dept Histopathol, Manchester M20 4BX, Lancs, England
关键词
myofibroblast; fibrosis; cancer; tumour; stroma; ultrastructure; therapy;
D O I
10.1111/j.1582-4934.2007.00213.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The phrase 'translational research'conveys the idea of the pursuit of applications for the treatment of human disease.The myofibroblast, long known for having a role in wound-healing, and for its presence in fibrotic conditions and tumour stroma, is becoming a focus for translational research, not least through its increasingly documented role as a tumour-promoting cell.In fibroproliferative conditions, cancer and tissue engineering, the myofibroblast, derived partly and possibly from circulating bone-marrow-derived cells and epithelial-to-mesenchymal transformation, is attracting great attention.In cancer, this cell was initially regarded as a barrier to tumour dissemination, but there is now a growing body of evidence to indicate that it is an active participant in tumour progression.While the involvement of the myofibroblast in these pathological processes is pushing the myofibroblast into the limelight of translational medicine as a target for potential anti-fibrotic and anti-cancer therapy, there are still numerous indications from the literature that the myofibroblast is a poorly understood cell in terms of its differentiation.Partly, this is due to a failure to appreciate the contribution of electron microscopy to understanding the nature of this cell.This paper, therefore, is devoted to detailing the principal phenotypic characteristics of the myofibroblast and promotes the argument that understanding how the myofibroblast carries out its roles in normal biological and in pathological processes will be enhanced by a sound understanding of its cellular differentiation, which in turn arguably demands a significant ultrastructural input.
引用
收藏
页码:22 / 37
页数:16
相关论文
共 117 条
[1]   Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites [J].
Abe, R ;
Donnelly, SC ;
Peng, T ;
Bucala, R ;
Metz, CN .
JOURNAL OF IMMUNOLOGY, 2001, 166 (12) :7556-7562
[2]   ANTI-TRANSFORMING GROWTH-FACTOR (TGF)-BETA ANTIBODIES INHIBIT BREAST-CANCER CELL TUMORIGENICITY AND INCREASE MOUSE SPLEEN NATURAL-KILLER-CELL ACTIVITY - IMPLICATIONS FOR A POSSIBLE ROLE OF TUMOR-CELL HOST TGF-BETA INTERACTIONS IN HUMAN BREAST-CANCER PROGRESSION [J].
ARTEAGA, CL ;
HURD, SD ;
WINNIER, AR ;
JOHNSON, MD ;
FENDLY, BM ;
FORBES, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2569-2576
[3]  
AUMULLER G, 1990, SMOOTH MUSCLE MALE G, pCH9
[4]  
BALAZS M, 1989, HISTOPATHOLOGY, V14, P434, DOI 10.1111/j.1365-2559.1989.tb02176.x
[5]   CD34+ fibrocytes, α-smooth muscle antigen-positive myofibroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx [J].
Barth, PJ ;
Schweinsberg, TSZ ;
Ramaswamy, A ;
Moll, R .
VIRCHOWS ARCHIV, 2004, 444 (03) :231-234
[6]   MIGRATION OF FIBROBLASTS IN PERIODONTAL-LIGAMENT OF MOUSE INCISOR AS REVEALED BY AUTORADIOGRAPHY [J].
BEERTSEN, W .
ARCHIVES OF ORAL BIOLOGY, 1975, 20 (10) :659-&
[7]   Smooth muscle cells healing atherosclerotic plaque disruptions are of local, not blood, origin in apolipoprotein E knockout mice [J].
Bentzon, Jacob F. ;
Sondergaard, Claus S. ;
Kassem, Moustapha ;
Falk, Erling .
CIRCULATION, 2007, 116 (18) :2053-2061
[9]   APPEARANCE OF THE MYOFIBROBLASTIC PHENOTYPE IN DUPUYTRENS DISEASE IS ASSOCIATED WITH A FIBRONECTIN, LAMININ, COLLAGEN TYPE-IV AND TENASCIN EXTRACELLULAR-MATRIX [J].
BERNDT, A ;
KOSMEHL, H ;
KATENKAMP, D ;
TAUCHMANN, V .
PATHOBIOLOGY, 1994, 62 (02) :55-&
[10]   TIME-DEPENDENT PERICELLULAR EXPRESSION OF COLLAGEN TYPE-IV, LAMININ, AND HEPARAN-SULFATE PROTEOGLYCAN IN MYOFIBROBLASTS [J].
BETZ, P ;
NERLICH, A ;
WILSKE, J ;
TUBEL, J ;
WIEST, I ;
PENNING, R ;
EISENMENGER, W .
INTERNATIONAL JOURNAL OF LEGAL MEDICINE, 1992, 105 (03) :169-172